Comparison of Second-Line Treatments of Recurrent and/or Metastatic Squamous Cell Carcinoma of the Head and Neck

References

• WHO . Fact sheets by cancer [Internet]. 2012, 4 (2012). http://globocan.iarc.fr/Pages/fact_sheets_cancer.aspx
   Google Scholar
• Argiris A , KaramouzisMV, RabenD, FerrisRL. Head and neck cancer. Lancet371(9625), 1695–1709 (2008).
   PubMed Web of Science ®Google Scholar
• Price KAR , CohenEE. Current treatment options for metastatic head and neck cancer. Curr. Treat. Options Oncol.13(1), 35–46 (2012).
   PubMed Web of Science ®Google Scholar
• Vermorken JB , MesiaR, RiveraFet al. Platinum-based chemotherapy plus cetuximab in head and neck cancer. N. Engl. J. Med.359(11), 1116–1127 (2008).
   PubMed Web of Science ®Google Scholar
• Guigay J , FayetteJ, DilliesAFet al. Cetuximab, docetaxel, and cisplatin as first-line treatment in patients with recurrent or metastatic head and neck squamous cell carcinoma: a multicenter, Phase II GORTEC study. Ann. Oncol.26(9), 1941–1947 (2015).
   PubMed Web of Science ®Google Scholar
• Tahara M , KiyotaN, YokotaTet al. Phase II trial of combination treatment with paclitaxel, carboplatin and cetuximab (PCE) as first-line treatment in patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck (CSPOR-HN02). J. Clin. Oncol.34(15 Suppl.), 6026–6026 (2016).
   Google Scholar
• Argiris A , HarringtonKJ, TaharaMet al. Evidence-based treatment options in recurrent and/or metastatic squamous cell carcinoma of the head and neck. Front. Oncol.7, 72 (2017).
   PubMed Web of Science ®Google Scholar
• Peyrade F , CupissolD, GeoffroisLet al. Systemic treatment and medical management of metastatic squamous cell carcinoma of the head and neck: review of the literature and proposal for management changes. Oral Oncol.49(6), 482–491 (2013).
   PubMed Web of Science ®Google Scholar
• Guardiola E , PeyradeF, ChaigneauLet al. Results of a randomised Phase II study comparing docetaxel with methotrexate in patients with recurrent head and neck cancer. Eur. J. Cancer40(14), 2071–2076 (2004).
   PubMed Web of Science ®Google Scholar
• Ferris RL , BlumenscheinG, FayetteJet al. Nivolumab for recurrent squamous-cell carcinoma of the head and neck. N. Engl. J. Med.375(19), 1856–1867 (2016).
   PubMed Web of Science ®Google Scholar
• Vermorken JB , HerbstRS, LeonX, AmellalN, BaselgaJ. Overview of the efficacy of cetuximab in recurrent and/or metastatic squamous cell carcinoma of the head and neck in patients who previously failed platinum-based therapies. Cancer112(12), 2710–2719 (2008).
   PubMed Web of Science ®Google Scholar
• Knoedler M , GaulerTC, GruenwaldVet al. Phase II study of cetuximab in combination with docetaxel in patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck after platinum-containing therapy: a multicenter study of the Arbeitsgemeinschaft Internistische Onkologie. Oncology84(5), 284–289 (2013).
   PubMed Web of Science ®Google Scholar
• Jiménez B , TrigoJM, PajaresBIet al. Efficacy and safety of weekly paclitaxel combined with cetuximab in the treatment of pretreated recurrent/metastatic head and neck cancer patients. Oral Oncol.49(2), 182–185 (2013).
   PubMed Web of Science ®Google Scholar
• Seiwert TY , BurtnessB, MehraRet al. Safety and clinical activity of pembrolizumab for treatment of recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-012): an open-label, multicentre, Phase 1b trial. Lancet Oncol.17(7), 956–965 (2016).
   PubMed Web of Science ®Google Scholar
• Moher D , LiberatiA, TetzlaffJ, AltmanDG, PRISMA Group. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. Ann. Intern. Med.151(4), 264–269, W64 (2009).
   PubMed Web of Science ®Google Scholar
• Doi SAR , BarendregtJJ, KhanS, ThalibL, WilliamsGM. Advances in the meta-analysis of heterogeneous clinical trials I: the inverse variance heterogeneity model. Contemp. Clin. Trials45(Pt A), 130–138 (2015).
   PubMed Web of Science ®Google Scholar
• Cohen EE , HarringtonKJ, Le TourneauCet al. Pembrolizumab (pembro) vs standard of care (SOC) for recurrent or metastatic head and neck squamous cell carcinoma (R/M HNSCC): Phase III KEYNOTE-040 trial. Ann. Oncol.28(Suppl. 5), v605–v649 (2017).
   Google Scholar
• Machiels J-P , SubramanianS, RuzsaAet al. Zalutumumab plus best supportive care versus best supportive care alone in patients with recurrent or metastatic squamous-cell carcinoma of the head and neck after failure of platinum-based chemotherapy: an open-label, randomised Phase 3 trial. Lancet Oncol.12(4), 333–343 (2011).
   PubMed Web of Science ®Google Scholar
• Argiris A , GhebremichaelM, GilbertJet al. Phase III randomized, placebo-controlled trial of docetaxel with or without gefitinib in recurrent or metastatic head and neck cancer: an Eastern Cooperative Oncology Group trial. J. Clin. Oncol.31(11), 1405–1414 (2013).
   PubMed Web of Science ®Google Scholar
• Stewart JSW , CohenEEW, LicitraLet al. Phase III study of gefitinib compared with intravenous methotrexate for recurrent squamous cell carcinoma of the head and neck [corrected]. J. Clin. Oncol.27(11), 1864–1871 (2009).
   PubMed Web of Science ®Google Scholar
• Machiels J-PH , HaddadRI, FayetteJet al. Afatinib versus methotrexate as second-line treatment in patients with recurrent or metastatic squamous-cell carcinoma of the head and neck progressing on or after platinum-based therapy (LUX-Head&Neck 1): an open-label, randomised Phase 3 trial. Lancet Oncol.16(5), 583–594 (2015).
   PubMed Web of Science ®Google Scholar
• Ferris RL , BlumenscheinG, FayetteJet al. Nivolumab for recurrent squamous-cell carcinoma of the head and neck. N. Engl. J. Med.375(19), 1856–1867 (2016).
   PubMed Web of Science ®Google Scholar
• Soulières D , FaivreS, MesíaRet al. Buparlisib and paclitaxel in patients with platinum-pretreated recurrent or metastatic squamous cell carcinoma of the head and neck (BERIL-1): a randomised, double-blind, placebo-controlled Phase 2 trial. Lancet Oncol.18(3), 323–335 (2017).
   PubMed Web of Science ®Google Scholar
• Seiwert TY , FayetteJ, CupissolDet al. A randomized, Phase II study of afatinib versus cetuximab in metastatic or recurrent squamous cell carcinoma of the head and neck. Ann. Oncol.25(9), 1813–1820 (2014).
   PubMed Web of Science ®Google Scholar
• Limaye S , RileyS, ZhaoSet al. A randomized Phase II study of docetaxel with orwithout vandetanib in recurrent or metastatic squamous cell carcinoma of headand neck (SCCHN). Oral Oncol.49(8), 835–841 (2013).
   PubMed Web of Science ®Google Scholar
• Büntzel J , MickeO. Second-line chemotherapy in head and neck cancer: what should we expect?Expert Rev. Anticancer Ther.9(3), 269–273 (2009).
   PubMed Web of Science ®Google Scholar
• de Andrade DAP , MachielsJ-P. Treatment options for patients with recurrent or metastatic squamous cell carcinoma of the head and neck, who progress after platinum-based chemotherapy. Curr. Opin. Oncol.24(3), 211–217 (2012).
   PubMed Web of Science ®Google Scholar
• Colevas AD . Chemotherapy options for patients with metastatic or recurrent squamous cell carcinoma of the head and neck. J. Clin. Oncol.24(17), 2644–2652 (2006).
   PubMed Web of Science ®Google Scholar
• Ang KK , HarrisJ, WheelerRet al. Human papillomavirus and survival of patients with oropharyngeal cancer. N. Engl. J. Med.363(1), 24–35 (2010).
   PubMed Web of Science ®Google Scholar
• Fakhry C , WestraWH, LiSet al. Improved survival of patients with human papillomavirus-positive head and neck squamous cell carcinoma in a prospective clinical trial. J. Natl Cancer Inst.100(4), 261–269 (2008).
   PubMedGoogle Scholar